Day: April 23, 2025

– Oral presentation will serve as first presentation of detailed results from the Phase 3 VERITAC-2 clinical trial – NEW HAVEN, Conn., April 23, 2025 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN) today announced that data from the global Phase 3 VERITAC-2 clinical trial (NCT05654623) evaluating vepdegestrant versus fulvestrant in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer will be presented as a late-breaking oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30 – June 3 in Chicago, IL. The presentation includes the first pivotal data for vepdegestrant, a potential first-in-class investigational oral PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader. Vepdegestrant...

TORONTO, April 23, 2025 (GLOBE NEWSWIRE) — Class 1 Nickel and Technologies Limited (CSE: NICO | OTCQB: NICLF) (“Class 1” or the “Company”) is pleased to announce that it has completed the previously announced airborne geophysical survey (see news release dated 12 March 2025) over its River Valley PGE-Cu-Ni Project (the “RV Project”), located about 65 kilometres northeast of the City of Sudbury, Ontario, Canada. The RV Project covers about 2,916 ha, within which lies several kilometres of prospective geology and known PGE-bearing sulphide mineralization categorized as Contact-Style PGE-Cu-Ni hosted by the River Valley Intrusion (“RVI”). The Company had engaged Geotech Ltd (“Geotech”) to fly a helicopter-borne VTEMTM Plus time-domain electromagnetic and horizontal magnetic-gradiometric survey (the “Survey”) over...

– ASCO Presentation to Highlight Preclinical Efficacy of SLS009 (tambiciclib) in ASXL1 Mutated Colorectal Cancer – NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that preclinical efficacy of SLS009 in ASXL1 mutated colorectal cancer lines will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, to take place May 30- June 3, 2025 in Chicago, Illinois. Poster presentation details: Title: In vitro efficacy of CDK9 inhibitor tambiciclib (SLS009) in ASXL1 mutated colorectal cancer cell lines. Session Date and Time: Monday, June 2, 2025, 1:30 PM-4:30 PM CDT Session Title: Developmental...

Reykjavík, April 23, 2025 (GLOBE NEWSWIRE) — (“Amaroq” or the “Company”) Block Listing Six Monthly Return and Notification of Major Holdings TORONTO, ONTARIO – 23 April 2025 – Amaroq Minerals Ltd. (AIM, TSX-V, NASDAQ Iceland: AMRQ), an independent mining company with a substantial land package of gold and strategic mineral assets in Southern Greenland, today makes the following notification pursuant to Schedule Six of the AIM Rules for Companies, regarding its existing block admission arrangements in connection with the Amaroq Minerals Stock Option Plan.Name of applicant: Amaroq Minerals LtdName of scheme: Amaroq Minerals ltd. Stock Option PlanPeriod of return: From: 24 October 2024 To: 23 April 2025Balance of unallotted securities under scheme(s) from previous return: 9,257,487Plus: The amount by which the block...

– Oral presentation at ASCO to highlight topline Phase 2 data of elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) in first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) CHICAGO and FORT WORTH, Texas, April 23, 2025 (GLOBE NEWSWIRE) — Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced that topline clinical data from the randomized Phase 2 study (Actuate-1801 Part 3B) evaluating elraglusib have been selected for oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, to take place May 30- June 3, in Chicago, Illinois. Details...

Today, the Board of Directors of Havila Shipping ASA has approved the financial statements for 2024 for both the Group and the parent company. The numbers are in line with preliminary accounts released on 26  February 2025. Contacts: Chief Executive Officer Njål Sævik, +47 909 35 722Chief Financial Officer Arne Johan Dale, +47 909 87 706 This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading ActAttachmentsHAVI20245967007LIEEXZXFJ8876-2024-12-31-no

ALK (ALKB.DC / OMX: ALK B) today announced that its European regulatory filing for ITULAZAX® (tree pollen sublingual allergy immunotherapy tablet) for treatment of young children and adolescents aged five to 17 has been approved by the health authorities in 17 EU countries via a type II variation procedure. First market introductions are expected to follow in the coming months ahead of the 2025/2026 initiation season for new patients starting treatment on pollen allergy tablets. Executive Vice President of R&D, Henriette Mersebach (MD), says: “We are very pleased with the European health authorities’ approval which allows us to provide this important treatment option to children and adolescents whose lives are impaired by uncontrolled tree pollen-induced respiratory allergy. Today’s approval marks another significant milestone...